Copyright restrictions may apply. Please see our Conditions of Use.
| ||||||||||
|
Downloading the PowerPoint slide may take up to 30 seconds. If the slide opens in your browser, select File -> Save As to save it. Copyright restrictions may apply. Please see our Conditions of Use. |
|
|||||||||||
Figure 2. Percentage of patients with no or mild clinical disability 60 or 120 minutes after dosing with sumatriptan hemisulfate nasal spray (5, 10, or 20 mg) or placebo. Asterisk indicates P<.05 vs placebo; dagger, P<.05 vs 5 mg of sumatriptan hemisulfate nasal spray.
